Acotec Scientific Holdings SEHK 6669 Margin Jump To 18.5% Tests Premium Valuation Narratives

Simply Wall St.

Mar 27

Acotec Scientific Holdings (SEHK:6669) has opened FY 2025 with first half revenue of C¥351.2 million and basic EPS of C¥0.29, alongside trailing twelve month EPS of C¥0.40 that reflects earnings ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2622827873"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622827873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622827873?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-03-27 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622827873","market":"sg","top_or_hot":-1,"title":"Acotec Scientific Holdings SEHK 6669 Margin Jump To 18.5% Tests Premium Valuation Narratives","media":"Simply Wall St.","content":"<div>\n<p>Acotec Scientific Holdings (SEHK:6669) has opened FY 2025 with first half revenue of C¥351.2 million and basic EPS of C¥0.29, alongside trailing twelve month EPS of C¥0.40 that reflects earnings ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-6669/acotec-scientific-holdings-shares/news/acotec-scientific-holdings-sehk-6669-margin-jump-to-185-test\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acotec Scientific Holdings SEHK 6669 Margin Jump To 18.5% Tests Premium Valuation Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcotec Scientific Holdings SEHK 6669 Margin Jump To 18.5% Tests Premium Valuation Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 20:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/healthcare/hkg-6669/acotec-scientific-holdings-shares/news/acotec-scientific-holdings-sehk-6669-margin-jump-to-185-test><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Acotec Scientific Holdings (SEHK:6669) has opened FY 2025 with first half revenue of C¥351.2 million and basic EPS of C¥0.29, alongside trailing twelve month EPS of C¥0.40 that reflects earnings ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-6669/acotec-scientific-holdings-shares/news/acotec-scientific-holdings-sehk-6669-margin-jump-to-185-test\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-6669/acotec-scientific-holdings-shares/news/acotec-scientific-holdings-sehk-6669-margin-jump-to-185-test","article_id":"2622827873","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-6669/acotec-scientific-holdings-shares/news/acotec-scientific-holdings-sehk-6669-margin-jump-to-185-test","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622827873","pubTimestamp":1774614391,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Acotec Scientific Holdings (SEHK:6669) has opened FY 2025 with first half revenue of C¥351.2 million and basic EPS of C¥0.29, alongside trailing twelve month EPS of C¥0.40 that reflects earnings growth of 128% over the past year and a trailing net profit margin of 18.5% versus 9.8% a year earlier. The company has seen revenue move from C¥292.3 million in 1H 2024 to C¥241.6 million in 2H 2024 and then to C¥351.2 million in 1H 2025, while basic EPS across those periods has shifted from C¥0.13...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1587":"次新股","BK1100":"医疗保健设备","06669":"先瑞达医疗-B"},"translate_title":"先瑞达科技控股SEHK 6669利润率跃升至18.5%考验溢价估值叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06669":0.9},"content_text":"Acotec Scientific Holdings (SEHK:6669) has opened FY 2025 with first half revenue of C¥351.2 million and basic EPS of C¥0.29, alongside trailing twelve month EPS of C¥0.40 that reflects earnings growth of 128% over the past year and a trailing net profit margin of 18.5% versus 9.8% a year earlier. The company has seen revenue move from C¥292.3 million in 1H 2024 to C¥241.6 million in 2H 2024 and then to C¥351.2 million in 1H 2025, while basic EPS across those periods has shifted from C¥0.13 to C¥0.04 and then to C¥0.29. This gives investors a clear view of the recent earnings swing and margin progression. With that backdrop, the latest results point to profitability that is increasingly central to how the story around Acotec’s business is being framed. See our full analysis for Acotec Scientific Holdings. With the headline numbers in place, the next step is to set these results against the most widely discussed narratives around Acotec Scientific Holdings and see where the data supports the story and where it challenges it. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:6669 Revenue & Expenses Breakdown as at Mar 2026 AdvertisementProfit swings from C¥12.3m to C¥88.6m across halves  Net income moved from C¥12.3m in 2H 2024 to C¥88.6m in 1H 2025, with basic EPS shifting from C¥0.04 to C¥0.29 over the same stretch. This lines up with the reported 128% earnings growth over the last 12 months. What stands out for a more bullish read is that trailing 12 month net income reached C¥119.2m on revenue of C¥644.6m and a net margin of 18.5%, up from 9.8% a year earlier. This supports the idea of a business that is now earning more on each C¥ of sales, even though the semi annual pattern from C¥39.96m to C¥12.32m to C¥88.58m shows that profit delivery is not smooth across halves.\n     Supporters can point to trailing basic EPS of C¥0.40 versus C¥0.17 a few periods earlier as evidence that the bigger picture is one of higher earnings, even if the 2H 2024 dip interrupts the run rate. At the same time, the wide swing in half yearly EPS from C¥0.13 in 1H 2024 to C¥0.04 in 2H 2024 and then to C¥0.29 in 1H 2025 is a reminder that the positive trailing margin story is built on a series of very different six month outcomes.    Stronger profitability and the swing in half yearly earnings have shifted how many investors think about this business, and community views pull those threads together in one place, which you can tap into through the Curious how numbers become stories that shape markets? Explore Community Narratives. 18.5% net margin meets 30x P/E  On the one hand, the trailing net profit margin is 18.5% versus 9.8% a year earlier. On the other hand, the shares trade on a 30x trailing P/E compared with 18.4x for peers and 16.8x for the wider Hong Kong Medical Equipment group. Critics highlight that paying a 30x P/E leaves little room for disappointment, and the numbers partly support that concern because the valuation premium is clear. Yet the revenue base over the last 12 months sits at C¥644.6m with net income of C¥119.2m, which means investors are paying up for a company that has improved margins but is still similar in scale to other listed medtech names.\n     The gap between the 30x trailing P/E and the 18.4x peer average is wide enough that any future period resembling the softer 2H 2024, when EPS was C¥0.04 on revenue of C¥241.6m, could weigh more heavily on sentiment than it would for cheaper peers. At the same time, the rise in trailing net margin to 18.5% alongside trailing EPS of C¥0.40 challenges the strict bearish view that the company is only priced for perfection, because there is now a track record of multi year profitability and higher margin than the prior 12 month stretch built into that multiple.    Share price sits 6.2% below DCF fair value  The current share price of HK$12.92 is about 6.2% below a DCF fair value of HK$13.78, which suggests a small gap between price and that modelled estimate, while the stock still trades on a 30x trailing P/E. Supporters of a more optimistic stance argue that the 128% trailing earnings growth and 18.5% net margin help justify both the premium P/E and a share price close to DCF fair value. The data gives some weight to that because trailing 12 month revenue of C¥644.6m and net income of C¥119.2m mean the business is already generating solid profits rather than just top line expansion.\n     The fact that the price is modestly below the HK$13.78 DCF fair value while still on a higher P/E than peers creates a tension between valuation frameworks, where a cash flow based view appears a bit more accommodating than simple multiples. At the same time, the sharp swing in half yearly results between C¥39.96m, C¥12.32m and C¥88.58m of net income shows why some investors may focus more on how repeatable the current 18.5% margin and C¥0.40 trailing EPS really are before leaning too hard on the DCF output.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Acotec Scientific Holdings's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If this mix of stronger margins, valuation tension and earnings swings leaves you undecided, now is the time to study the numbers yourself and test both the optimistic and cautious narratives against your own expectations, then see how those stack up against the 2 key rewards. See What Else Is Out There Acotec Scientific Holdings combines a 30x P/E with profit swings between halves, so any softer period or earnings wobble could pressure sentiment more quickly. If that kind of valuation premium and earnings volatility feels uncomfortable, you can quickly size up alternatives with stronger pricing support and steadier fundamentals using the 284 resilient stocks with low risk scores.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}